VIVUS Receives Compliance Notification From the FDA
MENLO PARK, Calif.--(BW HealthWire)--Nov. 20, 1997--VIVUS,
Inc. (NASDAQ:VVUS) today announced that it was notified by the U.S.
Food and Drug Administration (FDA) that its original manufacturing
facility is in compliance with the Agency's current Good
Manufacturing Practice (cGMP) requirements. This notification comes
after a recent re-inspection of the VIVUS manufacturing facility in
Lakewood, New Jersey. VIVUS is currently expanding its production
capacity by building out an additional 90,000 square-foot facility at
the same business park in New Jersey.
Founded in 1991, VIVUS, Inc. is a leader in the development of
advanced therapeutic systems for the treatment of erectile
dysfunction, commonly referred to as impotence. VIVUS has pioneered
a novel therapy for erectile dysfunction known as the transurethral
system for erection. This therapy consists of a proprietary,
non-invasive drug delivery system that delivers pharmacologic agents
via the urethra.
-0-
Note to Editors and Investors: Additional written materials,
recent releases and Company information are available through a
variety of sources, including the VIVUS home page (www.vivus.com) and
the VIVUS Fax-On-Demand Service (888/329-5719).
--30--cmc/sf* rn/sf
CONTACT:
VIVUS, Inc.
Nina W. Ferrari or David Yntema, 650/325-5511
IR@VIVUS.com
To edit your profile, go to keyword NewsProfiles.
For all of today's news, go to keyword News. |
